Payment overview · 2025
General Payments
$5,426.18
49 reported records · 16 companies
Healthcare provider profile · identity verified
Hui-Li Huang, MD
Allopathic & Osteopathic Physicians|Family Medicine · BRONX, NY · NPI 1851476972
Verified facts
What the public records show
CMS Open Payments records show Hui-Li Huang, MD received $5,426.18 in general payments during 2025 across 49 reported records.
ABBVIE INC. accounted for 20.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Shingrix by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $1,128.78 | 20.8% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $836.51 | 15.4% | 12 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $624.91 | 11.5% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $373.66 | 6.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $369.05 | 6.8% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $366.84 | 6.8% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $363.87 | 6.7% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $250.00 | 4.6% | 2 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $247.91 | 4.6% | 2 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $150.00 | 2.8% | 1 | 2025 |
| Luye Pharma (USA) Ltd. | Unresolved — no canonical attribution shown | $130.00 | 2.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $125.00 | 2.3% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $125.00 | 2.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $123.19 | 2.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $118.28 | 2.2% | 1 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $93.18 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $5,426.18 | 49 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $628.58 | 5 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $624.91 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $373.66 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $369.05 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $361.42 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $273.37 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $250.22 | 2 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $250.00 | 2 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $250.00 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $246.59 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $245.00 | 2 | 2025 |
Source payment records
|
|||||
| IQIRVO Normalized: iqirvo |
Drug | Ipsen Biopharmaceuticals, Inc | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| ERZOFRI EXTENDED-RELEASE Normalized: erzofri extended release |
Drug | Luye Pharma (USA) Ltd. | $130.00 | 1 | 2025 |
Source payment records
|
|||||
| HyperRAB Normalized: hyperrab |
Biological | Grifols USA, LLC | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $124.98 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $124.98 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $123.19 | 1 | 2025 |
Source payment records
|
|||||
| Xembify Normalized: xembify |
Biological | Grifols USA, LLC | $122.91 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $121.84 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $120.32 | 5 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $118.28 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $117.28 | 1 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $93.18 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $93.18 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $93.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 60 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 81 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 101 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
85 | 25 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
60 | 22 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
67 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
30 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
60 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
81 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
101 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 618 | 200 |
| Ezetimibe | Ezetimibe | 513 | 173 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 319 | 99 |
| Hydrochlorothiazide | Hydrochlorothiazide | 295 | 100 |
| Metformin Hcl | Metformin Hcl | 269 | 80 |
| Amlodipine Besylate | Amlodipine Besylate | 266 | 90 |
| Fluticasone Propionate | Fluticasone Propionate | 246 | 87 |
| Metoprolol Succinate | Metoprolol Succinate | 221 | 63 |
| Diclofenac Sodium | Diclofenac Sodium | 180 | 70 |
| Losartan Potassium | Losartan Potassium | 138 | 43 |
| Gabapentin | Gabapentin | 137 | 39 |
| Levothyroxine Sodium | Levothyroxine Sodium | 135 | 33 |
| Colesevelam Hcl | Colesevelam Hcl | 118 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 109 | 38 |
| Rybelsus | Semaglutide | 101 | 24 |
| Lisinopril | Lisinopril | 100 | 30 |
| Famotidine | Famotidine | 98 | 35 |
| Metformin Hcl Er | Metformin Hcl | 92 | 21 |
| Omeprazole | Omeprazole | 91 | 34 |
| Farxiga | Dapagliflozin Propanediol | 85 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 83 | 20 |
| Allopurinol | Allopurinol | 82 | 29 |
| Ozempic | Semaglutide | 81 | 17 |
| Trazodone Hcl | Trazodone Hcl | 69 | 16 |
| Furosemide | Furosemide | 68 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 27 |
| Eliquis | Apixaban | 67 | 18 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 65 | 18 |
| Alendronate Sodium | Alendronate Sodium | 62 | 23 |
| Jardiance | Empagliflozin | 60 | 22 |
| Baclofen | Baclofen | 56 | 14 |
| Januvia | Sitagliptin Phosphate | 55 | suppressed |
| Ramipril | Ramipril | 55 | 16 |
| Nifedipine Er | Nifedipine | 54 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 54 | 25 |
| Ibuprofen | Ibuprofen | 53 | 20 |
| Novolog Flexpen | Insulin Aspart | 51 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 51 | 11 |
| Potassium Chloride | Potassium Chloride | 47 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 14 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 40 | 11 |
| Glimepiride | Glimepiride | 40 | 12 |
| Montelukast Sodium | Montelukast Sodium | 40 | 17 |
| Ammonium Lactate | Ammonium Lactate | 37 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 36 | 14 |
| Tresiba Flextouch U-200 | Insulin Degludec | 35 | suppressed |
| Nystatin | Nystatin | 34 | 20 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 33 | 12 |
| Single Use Swab | Alcohol Antiseptic Pads | 33 | 13 |
| Raloxifene Hcl | Raloxifene Hcl | 32 | suppressed |
| Valsartan | Valsartan | 32 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 30 | 23 |
| Tresiba Flextouch U-100 | Insulin Degludec | 29 | suppressed |
| Linzess | Linaclotide | 28 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 27 | 23 |
| Sertraline Hcl | Sertraline Hcl | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 26 | suppressed |
| Repatha Sureclick | Evolocumab | 25 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 25 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Nateglinide | Nateglinide | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Trulance | Plecanatide | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Prednisone | Prednisone | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 16 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Simvastatin | Simvastatin | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Carvedilol | Carvedilol | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Praluent Pen | Alirocumab | 12 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,426.18 · 49 records | ABBVIE INC. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, AIRSUPRA, AREXVY, Auvelity, BREZTRI, COBENFY, ERZOFRI EXTENDED-RELEASE, FREESTYLE LIBRE 3, GLYCATE, HyperRAB, IQIRVO, JARDIANCE, KISUNLA, Kerendia, NUZYRA, Ozempic, QULIPTA, RELTONE 200 MG, RELTONE 400 MG, RINVOQ, Rybelsus, SKYRIZI, Symbravo, UBRELVY, VRAYLAR, Wegovy, Xembify | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error